Saltar al contenido
República del Perú · Observatorio de la producción científica universitaria
OApol.org Observatorio de Inteligencia Científica Universitaria del Perú
OApol.org
Inicio Universidades Publicaciones Investigadores
Repositorios
Tesis y trabajos académicosRevistas
Indicadores
Ranking trimestralRanking por carreraObjetivos de Desarrollo SostenibleReporte OCDERed neuronal 3D
Acerca
MetodologíaPrivacidad

Selective Serotonin Reuptake Inhibitors Increase Gastrointestinal but Not Other Site Bleeding Risk in Left Ventricular Assist Device Patients: A Systematic Review and Meta-Analysis

Picado-Loaiza S.; Valverde N.N.G.; Sánchez F.Z.; Luiz L.; Rojas C.; Goebel N.; Rylski B.; Ayala R. · Journal of Cardiothoracic and Vascular Anesthesia (2025) · DOI: 10.1053/j.jvca.2025.07.018

Resumen

Objectives: To evaluate the association between selective serotonin reuptake inhibitor (SSRI) use and bleeding complications in patients with left ventricular assist devices (LVADs), with particular focus on gastrointestinal (GI) bleeding, overall bleeding risk, and international normalized ratio (INR) levels at the time of bleeding. Design: Systematic review and meta-analysis of observational studies. Setting: Multicenter studies conducted in tertiary care academic hospitals across the United States and Europe. Participants: A total of 1,108 adult patients with implanted LVADs, of whom 431 were on SSRI therapy and 677 served as controls without SSRI exposure. Interventions: Exposure to SSRIs prior to or during LVAD support, compared with no SSRI therapy. Results: The primary outcome was GI bleeding. Secondary outcomes included bleeding from any anatomical site and INR values at the time of GI bleeding. SSRI use was significantly associated with increased risk of GI bleeding (risk ratio 1.61, 95% confidence interval [CI]: 1.19-2.17; p = 0.0019), but the overall risk of bleeding from any anatomical site, including GI and non-GI sources, did not reach statistical significance (risk ratio 1.44, 95% CI: 0.86-2.39; p = 0.16) or INR values (mean difference 0.22, 95% CI: −0.71 to 1.16; p = 0.64). Sensitivity analyses and publication bias assessments supported the robustness of these findings. Conclusions: In patients with LVADs, SSRI use is associated with a significantly increased risk of GI bleeding. These findings highlight the need for individualized bleeding risk assessment and GI prophylaxis in LVAD patients requiring antidepressant therapy.

Instituciones: Universidad Peruana Cayetano Heredia